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Abstract

Currently patients with diabetes receive most of their treatments, including
insulin, subcutaneously. Developing a method to orally deliver proteins, peptides, and
potentially other therapeutics has the ability to increase patient compliance by making
treatments easier to administer. Utilizing the Vitamin B12 uptake pathway is one
proposed method of oral delivery of protein therapeutics.
We investigated a way to synthesize a carboxylic acid derivative of Vitamin
B12 (B12) that could increase the ease of its conjugation to proteins and peptides. The
5’-position of the ribose tail of B12 was oxidized using excess 2-iodoxybenzoic acid
(IBX) and 2-hydroxypyridine (HYP). The synthesis of this B12 derivative allows for
peptides, proteins, and other molecules to be conjugated to the 5’-position of the
ribose tail of B12 using an amide bond instead of a carbamate bond. Conjugation of a
simple amine-containing organic molecule, benzylamine , to this B12 derivative with a
40% yield supported the synthesis of the derivative and its potential to increase the
yield of B12 conjugate formation.
We also investigated a method to recombinately express C-peptide using a
SUMO system and Escherichia coli. The ability to deliver C-peptide orally using the
vitamin B12 uptake pathway would be an easy treatment to potentially reduce diabetic
neuropathy, a complication present in many patients with diabetes.
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1 Diabetes
1.1 Diabetes
Diabetes is a group of diseases categorized by high levels of blood glucose.
This can be a result of defective insulin production, use, or a combination of both.
The two main types of diabetes are type 1 and type 2. 1
1.1.1 Type 1 Diabetes
The onset of type 1 diabetes is due to the destruction of pancreatic beta cells
by the body’s immune system. Because these cells are the body’s only source of
insulin production, people with type 1 diabetes must receive insulin via an outside
source, usually an injection or a pump. Type 1 diabetes usually develops during
childhood or young adulthood and accounts for about 5% of all diagnosed cases of
diabetes. 1
1.1.2 Type 2 Diabetes
Type 2 diabetes usually begins when the body’s cells cannot use insulin
properly. The demand for insulin in the body then rises, which eventually causes the
pancreas to lose its ability to produce it. Aging, obesity, and family history are all
associated with the onset of type 2 diabetes. 1
1.2 Diabetes in the Unite States
The Center for Disease Control and Prevention (CDC) reports diabetes as the
seventh most common cause of death. It affects 25.8 million people or 8.3% of the
population in the United States. Diabetes is also the primary cause of kidney failure
and is a major contributor to stroke and heart disease. The CDC estimates that in 2010
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in the United States about 1.9 million people over the age of 20 were newly
diagnosed with diabetes. 1
1.3 Current Treatments
Diet, insulin, and oral medication are the main forms of treatment used to
regulate blood glucose levels in people with diabetes. People with type 1 diabetes
must have insulin to sustain life. However, many people with type 2 diabetes are able
to manage their disease by just eating healthy, exercising, and losing weight in
combination with oral medication. 12% of adults diagnosed with diabetes take insulin
only, 14% take insulin and oral medication, 58% take only oral medication, 16% do
not take either one. Self-management and education are also key aspects of the
treatment of diabetes.1
2

Vitamin B12
2.1 Structure
B12, a water-soluble organometallic compound, is the largest and most

complex of all of the vitamins. 2 B12 consists of a corrin ring with the metal cobalt(III)
at its center. 3 Cobalt has 6 coordination sites, 4 being occupied by nitrogens in the
corrin ring. The fifth site is occupied by a ligand on the ! side. In the active forms of
B12 in the human body, the ! ligand is a methyl group or a 5-deoxyadenosyl group
and the compounds are called methylcobalamin and 5-deoxyadenosylcobalamin,
respectively. In the form of B12 usually present in dietary supplements, the ! ligand is
a cyanide group and the compound is called cyanocobalamin. In the body,
cyanocobalamin is converted to its active forms.4 The 6th coordination site is occupied
by 5,6-dimethylbenzimidazole, which is linked to a 5 carbon sugar. This 5 carbon
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sugar is linked to a phosphate group that is attached to an amide group in the corrin
ring. 3 This structure can be seen in Figure 1 below.

Figure 1 Structure of Vitamin B12

2.2 B12 Uptake Pathway
B12 is an essential vitamin that cannot be synthesized by the human body. The
average adult diet consists of an intake of 1-5 µg of B12 a day. Once ingested,
proteases and the acidic environment of the gastrointestinal tract begin to break B12’s
peptide bonds in order to extract it from food.
B12’s uptake pathway (Figure 2) begins with the binding of B12 to salivary
haptcorrin (HC). The acidic conditions (pH<3) cause HC to have a high affinity for
B12. HC is then able to protect B12 from acid hydrolysis, which would normally occur
in an environment with such a low pH. Then the HC and B12 complex moves from the
stomach into the first section of the small intestine or the duodenum. The pH in the
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duodenum is higher than that of the stomach (>5.5), decreasing HC’s affinity for B12.
Enzymes from the pancreas also begin to digest HC, which frees the B12 to then bind
to intrinsic factor (IF). IF, a second transport protein, is produced in the gastric
mucosa
the pancreas.
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Previously, Petrus et al. reported on the development and characterization of an orally
active B12-insulin conjugate with hypoglycemic properties in the streptozotocin (STZ)-induced
diabetic rat model.#$ The oral administration of the B12-insulin conjugate resulted in a 4.7 fold
greater decrease in blood glucose levels compared to orally administrated insulin in the STZ rat
model. It was determined that the B12-LQVXOLQ¶VJOXFRVHORZHUing ability was a result of the use

5
3

The Use of Vitamin B12 in Oral Delivery
3.1 Background
Many therapeutic peptides and proteins are currently given intravenously.

Although oral administration of these therapeutics would be an ideal alternative route
of delivery in order to increase patience compliance and comfort, two main barriers
stand in the way. First of all, the acidic environment of the gastrointestinal tract
would degrade any protein or peptide, leaving it in an inactive form. Second of all,
the body does not have a method or pathway to absorb these peptides and proteins
from the gastrointestinal tract into the bloodstream. 5 If these two problems could be
solved, then the oral delivery of peptides and proteins would be a feasible method to
deliver medications, improving the lives of many. For example, the ability to deliver
insulin orally would increase the ease at which it can be administered to those with
diabetes. This could significantly increase patient compliance, lowering the
complications and deaths each year caused by diabetes.
The utilization of the B12 uptake pathway described in section 2.2 has been a
method of oral delivery of peptides and protein receiving increasing attention over the
past decade. If proteins and peptides can be conjugated to B12, B12’s mechanism for
delivery within the body naturally has ways to protect the proteins and peptides from
the acidic environment in the gastrointestinal tract and allow them to be absorbed into
the bloodstream. 5
3.2 Conjugation Sites
When coupling B12 and a peptide, protein, or any other molecule, it is
important that both entities maintain their biological function in the body. The
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functional sites of the peptide, protein, or molecule must still be intact in order to
work properly once it reaches the bloodstream. In addition, the sites on B12
recognized by the proteins in its uptake pathway must still be recognizable. There are
three major sites on B12 that are believed to not interfere with its recognition in its
uptake pathway. 5
1) The e peripheral propionamide on the corrin ring
2) The ribose 5’-hydroxy group
3) The phosphate unit on the " tail
These sites are highlighted in figure 3 below.

1

3

2

Figure 3: Potential sites of conjugation on B12
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C-peptide
4.1 Background
C-peptide is a protein that contains 31 amino acids. It is part of the proinsulin

(Figure 4) produced from pre-proinsulin translated off the ribosome and is
synthesized by the beta cells of the pancreas. After C-peptide is cleaved from

proinsulin, Insulin is released into the body in its active form, along with an
cleave between
residue 32 and 33 at the C-peptide/B-chain junction and residue 65 and
equimolar amount of C-peptide. For a long time, C-peptide was thought to be

C-peptide/A-chain."" The removal of extra basic residues at the C-terminal end of the B
biologically inert and therefore people with diabetes only received injections of

supplemental
not C-peptide.
recent studies have suggested that Cand C-terminal
end of insulin,
C-peptide
occursHowever,
by CPE.
peptide may serve a regulatory role in the body by contributing to vascular
homeostasis in various tissues. Upon the administration of C-peptide, a number of
cellular responses occur in insulin dependent patients with diabetes, such as a “rise in
blood flow to the kidneys, muscle, skin, and nerves in the diabetic state.” 6 For
patients with diabetes, the lack of C-peptide in combination with high blood glucose
levels reduces microvascular circulation, which can eventually lead to complications
like neuropathy. 5,6

Figure 4: Representation of Human Proinsulin
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Site-Selective Oxidation of Vitamin B12
5.1 Background
As mentioned prior, there are several potential sites for conjugation to B12,

however conjugation has most successfully occurred at (1) the 5’-hydroxyl group of
the ribose and (2) the e propionamide of the peripheral corrin ring (Figure 5).
Fortunately, neither site interferes with the proteins of the B12 uptake pathway.
Although the carboxylic acid derivative of the e propionamide group has been made,
it is low yielding and difficult to purify. This is partially attributed to the
simultaneous synthesis of the b-, d-, and e- acid derivatives. The 5’-hydroxyl group of
the ribose of B12 is a versatile site that could potentially be used for the synthesis of a
variety of B12 conjugates. However, limited chemistry with the hydroxyl group can be
performed and the conjugates synthesized using this site are done through a
carbamate or ester bond shown in Figure 6. This presents stability issues and the
potential for degradation. The selective oxidation of the 5’-hydroxyl group of B12 to a
carboxylic acid was done using 2-iodoxybenzoic acid (IBX). This has the potential to
increase the chemistry available at B12’s 5’-position and the ability to form conjugates
through a more stable amide bond (Figure 6). 8,9
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Ester Bond
Carbamate Bond

Amide Bond
Figure 6: Carbamate, Ester, and Amide Bond examples

5.1.1 2-Iodobenzoic Acid (IBX)
Hypervalent iodine reagents, like IBX, are used in many oxidation reactions.
Most iodinanes are advantageous for oxidations due to their availability, ability to
regenerate, mild reaction conditions, and stability in the presence of oxygen and
moisture. In literature it was found that the combination of IBX and NHydroxysuccinimide (NHS) produces activated esters and carboxylic acids from
alcohols. NHS is used as an activating agent that helps to bring the oxidation state
from the alcohol to the aldehyde all the way to the desired to the carboxylic acid.
Although the use of IBX for an oxidation reaction is seen in literature, this is the first
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time it has been utilized for a molecule like B12, expanding its array of possible
reactions. 10
5.2 Synthesis of 5’-Carboxylic Acid of B12 Ribose Tail
Beginning with the method developed by Giannis et al., a reaction to
synthesize the B12 carboxylic acid derivative was created. This reaction uses an Onucleophile, NHS, in conjunction with IBX to oxidize primary alcohols. The initial
use of NHS with IBX for the oxidation of the 5’-hydroxyl group on the ribose of B12,
resulted in a mixture of products from which the carboxylic acid could not be
isolated. This mixture of products was likely due to the simultaneous formation of the
activated ester along with the carboxylic acid. The activated ester has been reported to
be the dominant product of this reaction.10 2-hydroxypyridine (HYP) was then used
in place of the NHS as the O-nucleophile, which provide better results. The proposed
reaction mechanism can be seen in Figure 7.
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reaction. Conditions such as the co-oxidant, temperature, and the time were varied.
These results can be seen in Figure 8 below.

Co-oxidant

Temperature (°C)

Time (hours)

% Yield

None

50

2

17

HYP

50

2

23

HYP

50

3

26

HYP

50

4

28

HYP

50

5

22

HYP

60

2

30

Figure 8: Reaction Optimization

After many reactions, the optimal conditions were determined to be 5
equivalents of HYP for every 2.6 equivalents of IBX in DMSO at 60°C. As shown in
Figure 8, it resulted in a 30% yield of the 5’-carboxylic acid derivative of B12
(B12CA) over a two hour time period. It was also noted that using a temperature
above 60°C or a time deviating from two hours for this reaction increased the amount
of byproducts and/or degradation of B12, making the B12CA difficult to purify and
reducing its yield. In addition, using an IBX:HYP ratio that differed from 2.6:5
equivalents resulted in an increase of byproducts, and therefore a decrease in percent
yield of the B12CA. When comparing the synthesis of the B12CA to that of the e-
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carboxylic acid derivative (Figure 5), the purification process was much easier and
the yield was almost three times as high.8, 11
In order to prepare the reaction product for purification, it was precipitated out
of the DMSO into diethyl ether. The ether was decanted and the solid product was
allowed to air dry. The solid product was then re-dissolved in water.
The purification process was done using high-performance liquid
chromatography (HPLC) and an Agilent SAX analytical column (5 µm, 9.4 X 250
mm), which utilized ion exchange chromatography. Solvent A was ultra purified
water and solvent B was a 50:50 mixture by volume of Acetonitrile (MeCN) and
phosphate buffer pH 2. Note that an increase in pH for solvent B resulted in a
decrease in the amount of purified B12CA.
With a flow rate of 1 mL/minute, 100% of solvent A was allowed to flow
through the HPLC and column for 5 minutes. This was followed by a gradient from
100% solvent A, 0% solvent B to 65% solvent A, 35% solvent B over 5 minutes. The
HPLC profile can be seen in Figure 9 below. 8,11
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Absorbance

B12CA !

B12 and B12 5’-aldehyde
"

Time (minutes)
Figure 9: HPLC spectra of B12CA purification, monitored at 360 nm. The retention
time of the unreacted B12 and aldehyde was about 5 minutes and the B12CA was about
12 minutes.

The peak at a retention time of 5 minutes was identified as a mixture of
unreacted B12 and the ribose 5’-aldehyde B12 derivative. The peak with a retention
time of about 12 minutes was identified as B12CA, the desired product. The peak at
12 minutes, which was red in color, was collected and neutralized. It was mixed with
amberlite XAD4 resin and rocked overnight in order to remove any salt. The
amberlite resin turned red, suggesting the binding of the B12CA. The resin was
collected and washed with water to remove any excess salt. The resin was placed in
Methanol (MeOH), which would release the B12CA. The MeOH solution containing
the B12CA was collected and lyophilized to get rid of the MeOH and leave a red
powder product. 8,11
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5.3 Identification of B12CA
Various methods were chosen to support the identification of the synthesized
product as B12CA.
5.3.1

Matrix Assisted Laser Desorption Ionization (MALDI)

Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-ToF)
mass spectrometry was done using a Bruker Autoflex II Smartbeam machine with
laser intensity from 50-73%. A small sample of the purified product (B12CA) was
taken and mixed with a matrix containing "-cyano-4-hydroxycinnamic acid (CHCA)
in a 1:1 volume ratio of water and acetonitrile with 0.1% trifluoroacetic acid (TFA).
Angiotensin I was also added for use as an internal control, which has a mass to
charge ration (m/z) of 1296. The mass to charge ratio expected for a product
containing B12CA is m/z=1343.5 [M-CN]+. This peak was present in the MALDI
profile as shown in Figure 10, supporting the synthesis of B12CA.
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Figure 10: MALDI-ToF of the reaction product. At m/z=1296.7 the expected
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the HPLC peak at 5 seconds. The expected angiotensin

#

peaks can be seen at m/z=1296.7, B12 at m/z=1329.5, and the 5’-aldehyde B12
derivative at m/z= 1327.5.

5.3.2

Electron Absorption Spectroscopy (EAS)

Electron Absorption Spectroscopy (EAS) was used to determine the yield of
the B12CA product. The spectrum is shown in Figure 12 below. The yield was
!"#
 calculated using Beer-Lambert law in which A= #lc, where A is the absorption, # is

19
the extinction coefficient, l is the path length, and c is the concentration. For B12CA
the extinction coefficient used was #=27500 M-1cm-1.

Figure 12: Electronic Absorption Spectrum of B12CA taken in 35% B from HPLC run

F igure 45. Absorbance spectrum of 4 in 35 % HPLC mobile phase B.
5.3.3 1D and 2D Nuclear Magnetic Resonance Analysis of B12CA
4.2.2 1D and 2D N M R analysis of 4
Using 1H Nuclear Magnetic Resonance (NMR) (Figure 13) and 1H-13C
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was then chosen to further establish the
(Figure 16). The signal that disappears at $H=63.3 in the HSQC of B12CA indicated
addition of a carbonyl at the R5 position (see Figure 48), however it was established that
that the protons lost in going from B12 to B12CA were attached to the R5 carbon. 8, 11
the R5 carbon shows no connectivity to any of the ribose protons and so was assigned by
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F igure 46. 500 MHz 1H NMR spectrum of 4.
Figure 13: 500 MHz 1H NMR of B12CA

F igure 46. 500 MHz 1H NMR spectrum of 4.

.
F igure 47. 500 MHz 1H-13C HSQC NMR spectrum of 4.

.
1
F igure 47. 500 MHz
H-13C HSQC NMR spectrum of 4.
1
13
Figure 14: 500 MHz H- C HSQC NMR of B12CA
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Figure 15: 500 MHz 1H NMR of B12
F igure 49. 500 MHz 1H NMR spectrum of B12 (CNCbl).
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Figure
16: Zoomed in portion of 500
MHz 1H-=>13#./012&3%456(1#21(7F##
C HSQC NMR of B12 (left) and
2)7#EFGG;#7HB#'%#%4(72'(%)#2'#'@B#I.#12&3%)8
-#D#JKFL.;#()#'@B#<

B12CA (right). Note the loss of the protons at $H=3.75 and 3.92 when the carbon at103
R5
!

($H=63.3) is oxidized.
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5.4 Conjugation of Benzylamine to B12CA
Benzylamine was chosen to conjugate to the B12CA. Benzylamine is a simple
amine-containing organic molecule and was chosen because of its easily identifiable
diagnostic peaks present in an NMR profile. This would help to characterize the R5
carbon even further. In addition, it would help to confirm the synthesis of the B12CA
by showing that a simple amine could be conjugated to the carboxylic acid at the 5’
position on the ribose of B12.
5.4.1

Synthesis of Conjugate

The B12CA and benzylamine were dissolved in dimethylformamide (DMF)
containing 1% water, along with 10 molar equivalents of ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC) and 20 molar equivalents 1hydroxybenzotriazole (HOBt). This was left at room temperature for 1 hour to allow
the reaction to occur. During this time, the B12CA-benzylamine (B12CABA)
conjugate was synthesized with a 40% yield. The reaction is shown in figure 17
below.

1

F igure 51. Synthesis of 5.

Figure 17: The reaction of B12CA with benzylamine (1) to form B12CABA
5 was purified using the same purification method as established for the

usingcarboxylic
EDCacid
and
HOBt in DMF for 1 hour at room temperature.
(see Figure 52) and characterized by MALDI mass spectrometry (see
Figure 53) as well as 1D (see Figure 54) and 2D NMR (see Figure 55 and 56).
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5.4.2

Purification of Conjugate

Using the same HPLC method established to purify the B12CA from the
original reaction, the B12CABA was purified. This involved ion exchange with an
SAX column, a flow rate of 1 mL/minute, and 100% of solvent A flowing through the
F igure 51. Synthesis of 5.
HPLC and column for 5 minutes. This was followed by a gradient from 100% solvent
5 was purified
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purification
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for the
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B to 65%
solvent
A, 35%
solvent Bmethod
over 5asminutes.
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(see Figure
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andasphosphate
pH 2. 54)
Theand
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shown
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Figure 18: HPLC profile of B12CABA
F igure 52. Purification of the conjugate was established by RP-HPLC using an SAX
5.4.3 Identification of B12CABA
column with a gradient from 100% water to 35% MeCN: phosphate buffer pH 2.
The B12CABA was plated for MALDI, again using CHCA in a 1:1 volume
105
ratio
of
water
and
acetonitrile
with
0.1%
TFA.
Angiotensin
I
was
used
for
an
internal
!

control. The MALDI-ToF profile of B12CABA showed a mass to charge ratio of
m/z=1432.5, which is what was expected if the conjugations was successful (Figure
19). A close up of the benzylamine MALDI peaks can be seen in Figure 20.
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Figure 19: MALDI-TOF of the B12CABA. The expected angiotensin peaks can be
seen at m/z=1296.7 and B12CABA at m/z=1432.6
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Figure 20: Up close of figure 0 of the B12CABA m/z=1432.6.

Next, 1H NMR (Figure 21) of the B12CABA was done to further support the
synthesis of the B12CABA. Looking at the 1H NMR for the B12CABA and comparing
it to that of B12CA, the appearance of the set of peaks just below $H =7.5 is diagnostic
of the addition of the benzylamine.
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Figure 21: 500 MHz 1H NMR of B12CABA
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1

H-13C HSQC NMR (Figure 22) and 1H-13C HMBC NMR (Figure 23) were

#

also performed on the B12CABA to study the connectivity to the R5 carbon. From the
HMBC, it can be seen that the R5 carbon ($C=173.8 ppm) of B12CA is connected to
the two protons of CA of the benzyl amine ($H=4.42 and 4.50 ppm). The protons of
CA also show direct connectivity to CB ($C=140.8 ppm) and CC ($C= 131.4 ppm) of
the benzylamine. The numbering assignments of the atoms as well as the signal
assignments of the B12CABA for HSQC and HMBC can be seen in Figure 24. 8, 11
!"#
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Figure 22: 500 MHz 1H-13C HSQC NMR of B12CABA
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23: 500 MHz
C HMBC NMR of B12CABA
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F igure 56. 500 MHz 1H-13C HMBC of 5.
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Figure 24: A: Numbering assignments of B12CABA, B: Signal assignments of the
F igure
Analysis
of Signal
5 by assignments
2D heteronuclear
NMR spectroscopy.
HSQC57.
of B12
CABA, C:
of the HMBC
of B12CABA A . The atom
numbering scheme for the benzylamine attached to the R5 of B12 by an amide bond. B.

5.5 Conclusion
!

108

In conclusion, we have successfully made a derivative of B12 that could
increase the ease at which B12 conjugates are made. We have not only shown that IBX
can be used for the oxidation of B12, but this oxidation is site specific of the ribose 5’hydroxyl group. The B12CA is synthesized with a yield that triples the synthesis of the
carboxylic acid derivative of the propionamide or any other reported carboxylic acid
derivative of B12. It is also much easier to purify and quicker to make. The formation
of a derivative of B12 that has a carboxylic acid instead of a hydroxyl group available
for conjugation increases the chemistry that can be performed at the 5’ site. This will
allow higher yielding and more stable conjugates to be formed in the future. This
conjugate will be of significant use in the field of B12 conjugation chemistry. 8, 11
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NOTE: Section 5 information and images were all reproduced with permission and
acknowledgement to citations 8 and 11 in references.
6

Expression of C-peptide
6.1 Introduction
As mentioned prior, administration of C-peptide has the potential to reduce

diabetic neuropathy, a major complication that arises in many people with diabetes.
Currently a subcutaneous administration of C-peptide is being studied for use in
patients with diabetes7, however the ability to deliver C-peptide orally has the
potential to be more convenient for patients with diabetes and therefore increase
patient compliance. Utilization of the B12 uptake pathway by conjugating C-peptide to
the 5’-carboxylic acid derivate of B12 we have created (B12CA), could allow the oral
delivery of C-peptide.
6.2 Recombinant Expression of C-peptide
6.2.1 Sumo System
In order to create a conjugate of B12 and C-peptide, the first step was to
establish a method of expressing recombinant C-peptide. The system chosen to do so
with was a Small Ubiquitin-like Modifier (SUMO) system, made by the Lucigen
Corporation. The SUMO protein contains 100 amino acids and aids in the expression
of difficult target proteins by enhancing the protein’s solubility and expression. The
SUMO system contains a 6xHis-Sumo tag, which is used for purification. The SUMO
system also does not require purification of the PCR product or restriction enzymes
prior to ligation.
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6.2.2 Amplification of C-peptide
The target protein, C-peptide was amplified using Polymerase Chain Reaction
(PCR). Three different PCR reactions were done with a 1:10, 1:5, and 1:1 volume to
volume ratio of DNA to water. The DNA used was a pUC57 plasmid containing the
target gene C-peptide, which was ordered. The primers were also designed (Figure
25) based on the instructions in the Lucigen SUMO manual in order to synthesize the
C-peptide PCR product with the correct flanking sequences needed for the ligation
into the SUMO containing vector.

Forward Primer: 5’-CGCGAACAGATTGGAGGTGCGGAAGATCTGCAAGTG-3’
Reverse Primer: 5’-GTGGCGCCCGCTCTATTATTGCAGAGAGCCTTCCAG-3’
Figure 25: Primers for C-peptide Insertion into the SUMO system

The PCR mixture consisted of 10 µL of the different DNA to water ratios
described above, 20 µL of sterile water, 5 µL of a 10 µM concentration of the forward
primer, 5 µL of a 10 µM concentration of the reverse primer, 5 µL of thermopol
buffer, 4 µL of dNTPs, and 1 µL of deep vent enzyme. The PCR conditions were 34
cycles of 94°C for 1 minute, 60°C for 1 minute and 74 °C for 20 seconds.
The 3 different PCR products were then run down a DNA agarose gel (0.5
grams of agarose, 50 mL of 1X TBE buffer, 2.5 µL of Ethidium Bromide) for 70
minutes at 70 Volts (Figure 26). C-peptide plus the flanking sequences added for
ligation contains about 100 base pairs and can be seen in all 3 lanes of the varied PCR
reactions near the 0.100 kilobase marker, supporting its synthesis.
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Figure 26: Agarose Gel of PCR product. C-peptide plus the flanking sequences added
contain about 100 base pairs and can be seen at around the 0.100 kilobase marker in
all 3 lanes.
6.2.3 Ligation
The Lucigen Corporation Sumo kit contained a linearized pETite N-His
SUMO Kan vector, which includes the SUMO sequence. On each end of the
linearized sequence the flanking sequences are complementary to that of the C-

32
peptide PCR product made, which helps to ligate the C-peptide and the vector. The
ligation was done by adding 2 µL of the pETite vector linearized DNA and 3 µL of
the PCR product to thawed chemically competent HI-Control 10G cells. Lucigen
Corporation optimizes these cells for a high efficiency transformation. The cells were
allowed to sit on ice for 30 minutes, then they were heat shocked by being placed in
water at 42°C for 45 seconds. 960 µL of recovery media was added to the cells and
then the cells were left on ice for 2 minutes. Finally the cells were placed at 37°C for
1 hour. The cells were then plated on LB Kanamycin (Kan) Agar plates and incubated
at 37°C overnight. Single colonies that grew on the plates were selected and grown in
5 mL of LB and 5 µL of Kan overnight at 37°C, 250 RPM. The plasmid was then
isolated and sent for sequencing. The sequence confirmed that a successful ligation
had occurred between the C-peptide and the pETite N-His SUMO Kan vector.
6.2.4 Induction
Following the successful ligation, SUMO C-peptide was expressed from the
pETite N-His SUMO Kan vector. Single colonies were selected and grown in 5 mL
of LB and 5 µL of Kan overnight at 37°C, 250 RPM. In the morning, 0.5 mL of this
culture was taken and placed in 50 mL LB broth with 50 µL of Kan. It was grown at
37°C, 250 RPM until the OD600 was 0.4-0.6. The cultures were then induced with
either 5 µL of 1 mM isopropylthiogalactoside (IPTG) or 5 µL of 0.1 mM IPTG,
giving the final concentration of IPTG in either culture as 0.1 mM and 0.01 mM,
respectively. Samples of each culture were taken prior to the addition of IPTG, at 1
hour after, 4 hours, and overnight. The samples were poured into falcon tubes,
centrifuged, and decanted. Each sample was redissolved in 20 mM tris-HCl, 150 mM
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NaCl pH 7.2. The samples were then lysed by being sonicated on ice with 10 pulses,
2 minutes of incubation on ice, two times. They were then centrifuged and the
supernatant, containing the proteins, was collected.
6.2.5 Purification
The supernatant following the lysis was purified using Fast Protein Liquid
Chromatography (FPLC). A nickel resin HisTrap column was used, along with 20
mM Hepes, 0.5 M NaCl, pH 7.2 for solvent A and 20 mM Hepes, 0.5 M NaCL, pH
7.2 with 250 mM Imidizole for solvent B. 100% A was run through the column,
followed by 100% B. The histag in the sumo system first bound to the column during
the initial flow through of solvent A. It was then eluted as solvent B flowed through
the column and imidizole displaced it. The FPLC profile is shown in Figure 27.

Flow Through

Eluted

Figure 27: FPLC profile of SUMO C-peptide system.
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6.2.6 Cleavage of SUMO
In order to cleave the SUMO protein from C-peptide, the eluted from the
FPLC purification was collected and boiled for 5 minutes with 1.5 µL of
Dithiothreitol (DTT). 0.5 µL of the SUMO protease was added. The mixture was left
at 30°C for 1 hour. The SUMO protease recognizes SUMO’s tertiary structure and
cleaves at its terminal carboxyl group. In theory, it should leave the target protein (Cpeptide) without any extra residues. However, an SDS-Page gel was done (Figure 28)
and showed that the C-peptide was not being cleaved from the SUMO system. If Cpeptide was cleaved from the SUMO protein, then after the digestion there should be
two bands, one for each the SUMO and C-peptide. In the gel in Figure 28, there is
only one band that did not change position after the digestion. SUMO is about 18 kDa
and C-peptide is about 3 kDa.
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Figure 28: SDS-Page gel. Lane 1: Low range protein ladder markers, Lane 2: Preinduction control, Lane 3: Overnight induction crude, Lane 4: FPLC flow through,
Lane 5: FPLC eluted, Lane 6: After Dialysis, Lane 7: Digestion

Different conditions were changed in order to try and get the cleavage to
occur. This included varying the temperature, the use of DTT and urea, and the
protease concentration and type. However, after many attempts at cleavage of the
SUMO protein and C-peptide, it was decided that a different method of cleavage was
necessary.
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6.2.7 The Addition of Factor Xa
Because the SUMO protease recognizes SUMO’s tertiary structure in order to
cleave the protein, it was decided a protease was needed that recognized a definitive
sequence and not a particular folding pattern. Factor Xa protease was chosen, which
cleaves after Arginine in the cleavage site Isoleucine-Glutamic Acid-GlycineArginine (IEGR). New primers were designed to incorporate the factor Xa site into Cpeptide (Figure 29).

Forward Primer:
5’CGCGAACAGATTGGAGGTATTGAAGGCCGCGAAGCGGAAG3’
Reverse Primer:
5’ GTGGCGGCCGCTCTATTATTGCAGAGAGCCTTCCAG3’
Figure 29: Primers for C-peptide with Factor Xa

The PCR product was amplified as in section 6.2.2 and ligated as in section
6.2.3 into HI-control 10G cells. After many attempts, it was clear that the ligation was
not occurring. Instead, a DNA sequence was ordered that contained SUMO, a Factor
Xa cleavage site, and C-peptide (Figure 30). Two different restriction sites were also
added to each end in order to digestion and ligate this DNA sequence into a vector,
pET-15b. Based on the restriction sites available in pET-15b, Nde1 and BamH1 were
chosen as the restriction enzymes/sites. The DNA sequence arrived in pUC57.
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A: Nde1His8SUMOFactorXaC-peptideBamH1StopCodon
B:
CATATGCATCACCATCACCATCACCATCACATATGCATCATCACCACC
ATCACGGGTCCCTGCAGGACTCAGAAGTCAATCAAGAAGCTAAGCCA
GAGGTCAAGCCAGAAGTCAAGCCTGAGACTCACATCAATTTAAAGGT
GTCCGATGGATCTTCAGAGATCTTCTTCAAGATCAAAAAGACCACTCC
TTTAAGAAGGCTGATGGAAGCGTTCGCTAAAAGACAGGGTAAGGAAA
TGGACTCCTTAACGTTCTTGTACGACGGTATTGAAATTCAAGCTGATC
AGACCCCTGAAGATTTGGACATGGAGGATAACGATATTATTGAGGCTC
ACCGCGAACAGATTGGAGGTATTGAAGGCCGCGAAGCGGAAGATCTG
CAGGTGGGCCAGGTGGAACTGGGCGGCGGCCCGGGCGCGGGCAGCC
TGCAGCCGCTGGCGCTGGAAGGCAGCCTGCAGGGATCCUAA
Figure 30: Ordered DNA sequence containing SUMO, Factor Xa, and C-peptide. A
shows a representation of the parts of the sequence and B shows the actual DNA
sequence

Once the DNA was received, both the DNA sequence and pET-15b were
digested to prepare for ligation. 4 µL of pET-15b, 1 µL Nde1 protease, 2 µL buffer 4,
and 11 µL of sterile water were mixed in one eppendorf tube. 4 µL of the ordered
DNA sequence in pUC57, 1 µL Nde1 protease, 2 µL buffer 4, and 11 µL of sterile
water were mixed in another eppendorf tube. Both were placed at 37°C for 30
minutes. Then to the pET-15b eppendorf tube, 1 µL Calf Intestinal Phosphatase (CIP)
and 1 µL of BamH1 were added To the DNA sequence eppendorf tube, 1 µL of sterile
water and 1 µL of BamH1 were added. Both reactions were placed back at 37°C for
60 minutes.
Using an agarose gel and the E.Z.N.A kit, the digested DNA (C-peptide) and
vector were purified and extracted. Molar ligations were performed in the following
ratios: 1:1 2 µL C-peptide/1 µL vector, 3:1 6 µL C-peptide/1 µL vector, 5:1 10 µL C-
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peptide/1 µL vector, 10:1 20 µL C-peptide/1 µL vector. To each of these, 2 µL of
buffer, 1 µL of T4 ligase, and enough sterile water to make each reaction mixture 21
µL were added to complete the ligation mixtures.
3 µL of each ligation mixture was then added to BL21(DE3) cells thawed on
ice to begin the transformation. The cells with the added ligation mixture were
incubated on ice for 30 minutes and then heat shocked for 45 seconds at 42°C. 960
µL of recovery media was added and the cells were allowed to sit on ice for 2
minutes. The cells were then plated on LB Ampicillin (AMP) Agar plates and grown
overnight at 37°C.
All of the plates grew as expected and twelve singles colonies were selected,
grown overnight in 5 mL LB, 5 µL AMP at 37°C, 250 rpm. The plasmid was isolated
from two of the cultures that had grown and sent for sequencing. The sequence
confirmed that a successful ligation had occurred between the C-peptide sequence
and the pET-15b vector.
The colonies with the correct sequences were selected, induced, and lysed as
in section 6.2.4. An SDS-Page gel was ran (Figure 31) of the various time points (preinduction, 1 hour after, 4 hours, overnight) and IPTG concentrations (0.1 mM and
0.01 mM). The gel did not show a band near 20-21 kDa, which is where the Sumo Cpeptide should appear. After multiple attempts, the cells did not appear to be lysing
properly, so a more effective method of lysing the cells is currently being developed
by increasing the length of sonication.
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Figure 31: SDS-Page gel of SUMO, Factor Xa, and C-peptide system after induction
and lysis. Lane 1: Precision Plus Protein Standards, Lane 2: Pre-induction control .01
IPTG, Lane 3: 1 hour .01 IPTG, Lane 4: 4 hours .01 IPTG, Lane 5: O/N .01 IPTG,
Lane 6: PIC 0.1 IPTG, Lane 7: 1 hour 0.1 IPTG, Lane 8: 4 hours, 0.1 IPTG, Lane 9:
O/N 0.1 IPTG

6.3 Conclusion
Although the cleavage of C-peptide from the SUMO system has not yet been
achieved, this work shows that the recombinant expression of C-peptide is possible
utilizing Escherichia Coli cells. The ability to recombinantly express C-peptide is a
low cost alternative to other methods currently available. Once a method of cleavage

40
is developed, C-peptide can be expressed and we can begin utilizing it for oral
delivery experiments using B12.

7

Future Work
7.1 C-peptide Expression and Confirmation
Once the cells are lysed properly, a purification method to isolate the SUMO

Xa C-peptide will be developed. Using the Factor Xa protease, we will cleave Cpeptide from the SUMO system. We will then purify the C-peptide using Factor Xa
binding beads.
After the recombinant expression and purification of C-peptide is achieved, we
are going to run diagnostic tests that support its synthesis. This will include a
Western blot and an Enzyme-linked immune sorbent assay (ELISA), which uses
antibody recognition to confirm C-peptide’s presence. Also, Circular Dichroism (CD)
will be conducted to determine the folding state and MALDI-ToF will be performed
to support the presence of C-peptide by using its mass to charge ratio.
7.2 Oral Delivery of C-peptide
Using the 5’-carboxylic acid B12 derivative we have made, we are going to
conjugate C-peptide to B12. In order to make the oral delivery of C-peptide feasible,
C-peptide cannot lose its function when conjugated to B12. C-peptide needs to be
conjugated using its carboxyl terminus. Because a carboxylic acid and carboxylic acid
cannot be coupled, a linker will be used. We will use ethylenediamine to link the 5’carboxylic acid to the carboxyl terminus of C-peptide. Although this will add two
carbons, it should allow C-peptide to maintain its function in the body.
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Capstone Summary

Diabetes is a group of disease categorized by high levels of blood glucose
(sugar). Insulin is a hormone produced by the body that regulates blood glucose
levels. Therefore, diabetes can be a result of defective insulin production, use, or a
combination of both. The two main types of diabetes are type 1 and type 2.
Currently patients with diabetes receive most of their treatments/therapeutics,
including insulin, subcutaneously via an injection or pump. Although oral
administration of these therapeutics would be an ideal alternative route of delivery in
order to increase patience compliance and comfort, two main barriers stand in the
way. First of all, the acidic environment of the stomach and digestive system would
degrade any protein or peptide that was ingested, leaving it unable to function
properly in the body. Second of all, the body does not have a method or pathway to
absorb these peptides and proteins into the bloodstream so they would just stay in the
digestive system and would not function in the body. If these two problems could be
solved, then the oral delivery of peptides and proteins would be a feasible method to
deliver medications, improving the lives of many. The ability to deliver insulin orally
would increase the ease at which it can be administered to those with diabetes. This
could significantly increase patient compliance, lowering the complications and
deaths each year caused by diabetes.
Utilizing the Vitamin B12 uptake pathway is one proposed method of oral
delivery of protein therapeutics. The utilization of the B12 uptake pathway has been a
method of oral delivery of peptides and protein receiving increasing attention over the
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past decade. If proteins and peptides can be linked or conjugated to B12, B12’s
pathway and mechanism for delivery within the body naturally has ways to protect
the proteins and peptides from the acidic environment in the gastrointestinal tract and
allow them to be absorbed into the bloodstream.
When coupling B12 and a peptide, protein, or any other molecule, it is
important that both entities maintain their biological function in the body. The
functional sites of the peptide, protein, or molecule must still be intact in order to
work properly once it reaches the bloodstream. In addition, the site on B12 recognized
by the proteins in its uptake pathways must still be recognizable. Therefore, vitamin
B12 only has select positions that a protein can be conjugated to.
Conjugation has most successfully occurred at (1) the 5’-hydroxyl group of
the ribose and (2) the e propionamide of the peripheral corrin ring. The 5’-hydroxyl
group of the ribose of B12 is a versatile site that could potentially be used for the
synthesis of a variety of B12 conjugates. However, limited chemistry with a hydroxyl
group can be performed and the conjugates synthesized using this site are done
through a carbamate or ester bond, which present stability issues. Also, it creates
potential for degradation or breaking of the bonds used to conjugate the two entities.
One way to solve this problem would be to change the hydroxyl group on B12 into a
group, such as a carboxylic acid, that allows for a greater variety of chemistry as well
as a more stable bond.
We investigated a way to synthesize a derivative of Vitamin B12 (B12) that
could increase the ease of its conjugation to proteins and peptides. The 5’-position of
the ribose tail of B12 was oxidized to a carboxylic acid using excess 2-iodoxybenzoic
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acid (IBX) and 2-hydroxypyridine (HYP). The synthesis of this B12 derivative allows
for peptides, proteins, and other molecules to be conjugated to the 5’-position of the
ribose tail of B12 using a more stable amide bond instead of a carbamate bond.
In conclusion, we have successfully made a form or derivative of B12 that
could increase the ease at which B12 conjugates are made. We have shown that IBX
can be used to specifically oxidize the 5’ site of B12. The B12 derivative synthesized
was done with a yield that triples the synthesis of any other reported carboxylic acid
derivative of B12. It is also much easier to purify and quicker to make. The formation
of a derivative of B12 that has a carboxylic acid instead of a hydroxyl group available
for conjugation increases the chemistry that can be performed at the 5’ site. This will
allow higher yielding and more stable conjugates to be formed in the future. This
conjugate will be of significant use in the field of B12 conjugation chemistry.
C-peptide is a protein that is part of the proinsulin. Proinsulin is the form of
insulin before it is activated for use as a hormone in the body. After C-peptide is
cleaved from proinsulin, Insulin is released into the body in its active form, along
with the same amount of C-peptide. For a long time, C-peptide was thought to be
biologically inactive and did not have a significant role in the body. People with
diabetes therefore only received injections of supplemental insulin, not C-peptide.
However, recent studies have suggested that C-peptide may serve a regulatory role in
the body by contributing to vascular homeostasis in various tissues. For patients with
diabetes, the lack of C-peptide in combination with high blood glucose levels reduces
circulation, which can eventually lead to complications like neuropathy. Neuropathy
is the disease or dysfunction of nerves. The administration of C-peptide has the
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potential to reduce diabetic neuropathy. Diabetic neuropathy most commonly leads to
limb amputations. Currently a subcutaneous administration of C-peptide is being
studied for use in patients with diabetes, however the ability to deliver C-peptide
orally has the potential to be more convenient for patients with diabetes and therefore
increase patient compliance. Utilization of the B12 uptake pathway by conjugating Cpeptide to the 5’-carboxylic acid derivate of B12 we have created (B12 CA), could
allow the oral delivery of C-peptide.
We have successfully created a method to recombinantely express C-peptide
using Escherichia coli or a type of bacteria. We have expressed C-peptide using a
SUMO system. The SUMO system is added in order to purify C-peptide and extract it
for use. The problem we are currently facing is cleaving or cutting C-peptide from the
SUMO system. Currently we are investigating alternative methods to solve this
problem. After this is completed, the next step will be conjugating C-peptide to B12
for oral delivery studies.
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Abstract: Reaction of vitamin B12 (B12) with excess 2-iodoxybenzoic acid and 2-hydroxypyridine leads to selective oxidation of the
5ƍ-hydroxyl group of the ribose tail of B12 in a 30% isolated yield.
The acid derivative was purified in one step by HPLC chromatography and characterized by MALDI-TOF mass spectrometry,
1
H NMR and 2D (HSQC and HMBC) NMR. The new carboxylic
acid derivative is perfectly suited to make stable amide-based B12
bioconjugates.

Interest in using vitamin B12 (B12) for the oral delivery of
peptides and proteins1 has encouraged us to further explore the available conjugate sites of B12. Modifications of
B12 that allow for more facile, higher yielding or stable
bioconjugate formation with continued recognition by B12
dietary uptake and transport proteins have been explored
by numerous groups.2–4 Several functional groups are
available on B12 for conjugation, including the 5ƍ-hydroxyl group of the ribose tail, the cobalt(III) ion, the phosphate moiety, and suitably modified propionamides off
the corrin ring.5 All such modifications suffer from issues
including reduced or complete loss of interaction with one
or more of the B12 binding proteins, stability issues that result from the production of ester or carbamate bonds, low
yielding conjugation reaction due to the nature of the
functional group, or require problematic purification of
the modified B12 for subsequent conjugation.2–4 These
limitations have been well investigated6 and a review of
such sites has been reported,7 however, in brief for purposes of perspective for the work described herein: Conjugation resulting in the recognition of all three transport
proteins has been most successful with B12 at two major
sites: (i) the peripheral corrin ring e-propionamide, and
(ii) the 5ƍ-hydroxyl group of the ribose unit of the a-‘tail’.
The side chain e-carboxylic acid derivative (Figure 1) allows for a variety of modifications,8 but the synthesis of
the derivative is low yielding and requires laborious purification, the result, in part, of the formation of b- and dcarboxylic acid isomers in addition to the desired e-isomer.9 The 5ƍ-hydroxyl group has been cited as being a
more versatile site according to structure–activity relationships, however, the conjugates have typically been
synthesized as mentioned above, through carbamate or ester bonds.
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Figure 1 Potential sites available for carboxylic acid formation that
also maintain, at least in part, B12 uptake protein recognition and binding are indicated in red. The atom numbering scheme used for NMR
discussion is also indicated

The goal of this work was to create a simple route for the
production of a 5ƍ-carboxylic acid derivative of B12 with
facile purification to ultimately produce stable amidelinked bioconjugates at this optimal position for conjugation, especially in regard to intrinsic factor binding (critical for oral uptake of B12 bioconjugates).10 Herein, we
report the use of the hypervalent iodine reagent, 2-iodoxybenzoic acid (IBX) for the selective oxidation of the
5ƍ-hydroxyl group of B12 to the corresponding carboxylic
acid. This is the first time IBX has been utilized for the oxidation of such a molecule as B12 and expands the range of
use of this environmentally friendly oxidizing agent.11
The B12 derivative was synthesized through a modification of the method developed by Giannis et al., which incorporates the addition of an O-nucleophile to aid IBX in
the transformation of a primary alcohol into a carboxylic
acid (Scheme 1).12 The use of N-hydroxysuccinimide
(NHS) was initially attempted but resulted in the formation of a product mixture from which it was not possible
to isolate the carboxylic acid, likely due to the formation
of the activated NHS ester, which has been reported as a
dominating product of this reaction.12 Therefore, 2-hydroxypyridine (HYP) was used as the O-nucleophile. To optimize the reaction conditions, a series of experiments were
performed in which the co-oxidant, temperature, and time
were varied (Table 1). The best result was obtained in the
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presence of 2.6 equivalents of IBX and 5 equivalents of
HYP in dimethyl sulfoxide (DMSO) at 60 °C.

Table 1 Optimization of the Reaction Conditions
Entry

Co-oxidant

Temp (°C)

Time (h)

Yield (%)

1

None

50

2

17

2

HYP

50

2

23

3

HYP

50

3

26

4

HYP

50

4

28

5

HYP

50

5

22

6

HYP

60

2

30

2). Slight increases in pH above pH 2 resulted in a reduction in the amount of pure isolated product. HPLC purification allowed the recovery and reuse of B12 starting
material, albeit with the oxidized 5ƍ-aldehyde also present
(Figure 2). B12CA was identified as the peak at 13.6 minutes retention time. The purity of B12CA was at least 95%,
as assayed by RP-HPLC. MALDI-TOF mass spectrometry analysis of B12CA revealed the anticipated molecular
ion peak (m/z = 1343.5 [M – CN]+; Figure 3).

Scheme 1 Purposed mechanism for the formation of the 5ƍ-carboxylic derivative utilizing IBX and HYP

These conditions resulted in the oxidation of B12 to the
5ƍ-carboxylic acid derivative B12CA in two hours with a
30% yield (see the Supporting Information). It was determined that a 30% yield was optimal for the IBX reaction
in this case. An increase in temperature, IBX/HYP ratios,
or time resulted in an increase in the amount of byproducts
and/or decomposition of the B12 (especially at temperatures in excess of 60 °C), reducing the yield and complicating purification. The 30% yield is approximately three
times that previously reported for the preparation of the ecarboxylic acid derivative, with far easier separation (see
below).9
The crude reaction mixture was precipitated from DMSO
by ether addition and the precipitate was redissolved in
water prior to purification by ion exchange chromatography using a SAX column. After a 5 minute hold at
100% water, a gradient from 100% water to 35% MeCN–
phosphate buffer (pH 2; 50:50 v/v) over 5 minutes was
necessary for the separation and elution of B12CA (Figure
Synlett 2012, 23, 2363–2366

Figure 2
The RP-HPLC spectra of 5ƍ-carboxylic acid
(tR = 13.6 min) monitored at 360 nm. Unreacted B12 and 5ƍ-aldehyde
co-elute at tR = ca. 5 min, as indicated by MALDI-TOF MS (see also
Figure S1 in the Supporting Information)

Electronic absorption spectroscopy (EAS) was used to establish the oxidation state of the metal center as Co(III),
with no indication of derivation of the axial ligands bound
to the metal center (İCA361 = 27500 M–1cm–1; see Figure 4)
The structure of B12CA was determined on the basis of 1H
NMR (see Figure S2) and 1H–13C heteronuclear (HSQC
and HMBC) correlations (see Figures S3 and S4). The 1H
NMR spectra of B12CA revealed the loss of two protons
(įH = 3.75 and 3.92 ppm), when compared to the spectrum
of B12 (CNCbl; see Figures S2 and S5). A comparison of
the HSQC of B12 and B12CA indicates the protons that are
absent in B12CA were originally attached to the R5 carbon
(įC = 63.5 ppm; see Figure S6). HMBC was attempted to
further establish the presence of a carbonyl at the R5 position (see Figure S4), however, it was not possible to assign the R5 carbon from the HMBC spectra because it
© Georg Thieme Verlag Stuttgart · New York
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Scheme 2 Synthesis of 5ƍ-carboxylic acid plus benzylamine

Figure 5 Purification of the conjugate was established by RP-HPLC
using an SAX column with a gradient from 100% water to 35%
MeCN–phosphate buffer pH 2

Figure 4 Absorbance spectrum of 5ƍ-carboxylic acid derivative in
35% HPLC mobile phase B

showed no connectivities to any of the ribose protons, and
so was assigned by HSQC.13
A simple amine-containing organic molecule, benzylamine, was conjugated to the derivative to help with the
identification of the R5 carbon by NMR analysis. In the
presence of 10 equivalents of ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and 20 equivalents 1-hydroxybenzotriazole (HOBt) in N,N-dimethylformamide (DMF)
with 1% water, the desired conjugate was produced at
40% yield over the first hour (Scheme 2), thus establishing proof-of-concept for the new B12CA.
The conjugate was purified by using the same purification
method established for the carboxylic acid (Figure 5) and
characterized by MALDI mass spectrometry (Figure S7)
as well as 1D (Figure S8) and 2D NMR (Figures S9 and
S10) spectroscopy.
With the addition of the benzylamine, connectivity to the
R5 carbon was established by HMBC (Figure 6). Specifically, the protons of CA (įH = 4.42 and 4.50 ppm) showed
direct connectivity to the R5 carbon (įC = 173.8 ppm) as
well as to CB (įC = 140.8 ppm) and CC (įC = 131.4 ppm)

© Georg Thieme Verlag Stuttgart · New York

Figure 6Analysis of the B12 5ƍ-carboxylic acid benzylamine derivative by 2D heteronuclear NMR spectroscopy. (A) The atom numbering scheme for the benzylamine attached to R5 of B12 by an amide
bond. (B) Signal assignments made from HSQC. (C) Signal assignments made from HMBC (both 1H and 13C assignment for CA were
made on the basis of HSQC analysis)

of the benzylamine. The complete assignment of B12CA
and B12CABA can be found in Table S1.
In conclusion, we have developed a convenient site-specific oxidation of B12 using IBX and HYP. This new carboxylic acid derivative is highly suited to the production
Synlett 2012, 23, 2363–2366
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Figure 3 MALDI-TOF MS spectrum of HPLC peak at tR = 13.6 min,
indicating B12CA (m/z = 1343.5 [M – CN]+) with angiotensin I (m/z =
1296.5) as an internal reference

S. Clardy-James et al.

of bioavailable amide bound bioconjugates. The one-step
purification is simple and the synthesis results in a 30%
yield within two hours, which is far in excess of any previously reported B12 carboxylic acid derivative.9 The resulting derivative has the potential to form high-yielding
conjugates and we believe will be of considerable use in
the field of B12 conjugation.
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